Table 2 Clinical response in the overall series and according to platinum sensitivity
N. | Complete N. (%) CI95% | Partial N. (%) CI95% | ORR N. (%) CI95% | Stable disease N. (%) CI95% | Clinical benefit N. (%) CI95% | PD N. (%) CI95% | p valuea | |
|---|---|---|---|---|---|---|---|---|
All cases | 54 | 3 ( 5.5) | 8 (14.8) | 11 (20.4) | 11 (20.4) | 22 (40.7) | 32 (59.2) | |
-0.58,11.6 | 5.3, 24.3 | 9.6,31.0 | 9.6,31.0 | 27.6, 53.8 | 46.1,72.3 | |||
Refractory | 20 | 1 ( 5.0) | 2 (10.0) | 3 (15.0) | 6 (30.0) | 9 (45.0) | 11 (55.0) | |
Resistant | -4.5, 14.6 | -3.1,23.1 | -0.6,30.6 | 9.9, 50.1 | 23.2, 66.8 | 33.2, 76.8 | ||
Sensitive | 34 | 2 ( 5.9) | 6 (17.6) | 8 (23.5) | 5 (14.7) | 13 (38.2) | 21 (61.7) | |
-2.0, 13.8 | 4.8,30.4 | 9,2,37.8 | 2.8, 26.7 | 21.9, 54.5 | 45.3, 78.0 | 0.5b |